FDA Recall Notification

Blaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contamination

Potential infection risk for vulnerable patients highlights critical quality system considerations

Recall Overview

Blaine Labs, Inc. has issued a voluntary nationwide recall of select lots of antiseptic wound care gel products due to microbial contamination.

Company: Blaine Labs, Inc.

Brand Names: Revitaderm®, Tridergel™

Product Type: Drug (Topical antiseptic)

FDA Publish Date: April 8, 2026

Reason: Presence of Lysinibacillus fusiformis

Affected Products

Affected products were distributed nationwide to healthcare providers (non-retail).

Revitaderm® Wound Care Antiseptic Gel (1 oz. & 3 oz.)

Active Ingredient: Benzalkonium Chloride 0.1%

Affected lots:

• BL3608 (Exp. 07/01/28)
• BL3435 (Exp. 11/06/26)
• BL3525 (Exp. 08/07/27)

Tridergel™ Wound Care (1 oz.)

Active Ingredient: Benzalkonium Chloride 0.1%

Affected lot: BL3435 (Exp. 11/06/26)

Risk Assessment

The contamination involves Lysinibacillus fusiformis, a spore-forming environmental organism. While generally low risk for healthy individuals, the risk profile changes significantly for patients with open wounds, diabetic patients, elderly individuals, and immunocompromised populations.

Potential outcomes include local infection, skin irritation, delayed wound healing, and severe complications (rare), that include endocarditis, a central nervous system infection.

Clinical Context

This recall is particularly notable because the product is intended to prevent infection. Contamination in this context represents a reversal of intended function, increasing risk rather than mitigating it.

MDP Regulatory and Quality Insight

This event highlights several critical areas of concern.

Microbiological Control in Non-Sterile Drug Products

Even though these are non-sterile topical products, they must meet microbial limits and have an absence of objectionable organisms.

The presence of a spore-forming organism suggests potential gaps in environmental control, inadequate preservative effectiveness, and possible manufacturing or packaging contamination pathways.

Risk-Based Product Use Consideration

Topical antiseptics that are used on broken skin or other compromised tissue functionally behave like higher-risk products. This raises the question of whether certain “non-sterile” products be tested with enhanced microbial controls?

Distribution Channel Risk

Products were distributed to physician offices and other clinical settings. This increases risk because product use is likely on vulnerable patient populations where traceability and recall effectiveness become critical.

CAPA and Root Cause Expectations

Regulators will expect a full root cause investigation, to include an evaluation of water systems, raw materials, environmental monitoring, and packaging integrity.

What Healthcare Providers Should Do

Healthcare providers who have these products should immediately identify and segregate affected lots, discontinue use and distribution, and contact Blaine Labs for return instructions.

Adverse Events

To date, no adverse events have been reported. However, given the risk population, monitoring is warranted.

MDP Perspective

This recall underscores a critical principle, that product classification does not always reflect real-world risk. A “non-sterile” topical product that is applied to compromised tissue, especially in vulnerable populations, can present risks closer to those of sterile products if contamination occurs.

Key Takeaways for Manufacturers

Manufacturers of topical products should reevaluate microbial control strategies, strengthen environmental monitoring programs, validate preservative systems rigorously, and consider risk-based escalation of controls for wound care products.

Contact Information

Blaine Labs, Inc.
📞 (800) 307-8818
📧 Contact@blainelabs.com

Links

Read the FDA’s announcement here.